KeyBanc maintained its ICU Medical [ICUI] rating to the equivalent of Overweight but changed the price target to $236 from $222, in a research note dated 2021-01-08. That figure represents around a 7.28% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with KeyBanc Capital Markets’s analysts upgrading the shares from “a Sector weight” rating to “an Overweight” rating in a research note to investors issued in mid March. Meanwhile, Raymond James had lowered its rating on ICUI to “an Outperform” from the earlier “Strong buy”, in a research note produced for clients August 08, 2019. In addition, KeyBanc Capital Mkts launched coverage on October 17, 2017. The research firm rated ICUI “a Sector weight”.
Is ICU Medical Inc. [NASDAQ:ICUI] a Good Buy Right Now?
It should be noted that ICUI technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 88% Buy in the last week and compares with 56% Buy in the past month. Data from ICU Medical Inc.’s Trend Spotter indicated that the signals were Weakening. The stock current average is 0.18 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.15 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 0.14 million shares.
ICUI Price Performance
On Wall Street, ICU Medical Inc. [NASDAQ:ICUI] finished Thursday’s session up 0.10% at $219.99. The stock went up to $220.00 at the same session while its lowest single day price was $217.33. In the last five days, it saw a rise of about 2.87%, ICU Medical Inc. shares gained by almost 2.56% since the beginning of the year. However, the share price has dropped to as low as -6.98% below its one year high. On 01/07/21, the company shares recorded $220.00, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $208.60. The company’s shares have inclined by 17.27% in the past year. The 50-day SMA achieved is $196.82 while the 200-day SMA is $194.04. Volume dropped to 0.21 million from 0.29 million in the previous session.
ICU Medical Inc. [ICUI] Valuation Measures
Notably, ICU Medical Inc. [ICUI] stock cannot be classified as a good candidate in the listing of underestimated low-priced Medical Instruments & Supplies companies to purchase soonest possible with the prevailing 12-month PE ratio of 58.18. The measure means the stock is exchanging at a premium as compared to the 33.86x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 3.63 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 5.23 which means ICUI serve an unattractive investment opportunity compared to its competitors.
ICUI Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 218.21 level, and in case of violation of this particular level, it will cause more drop to 216.44 level. On the upper level, 221.78 is still the key resistance. The stock may increase to the subsequent resistance at 220.88. The Relative Strength Index (RSI) pinned on the 14-day chart is 71.09, implying a overbought technical stance while the MACD stands at 6.06, meaning price will increase in the next trading period. Percent R indicator moved to 0.06%, implying bullish price movement. Stochastic %K at 99.31% suggest selling the stock.
What is the short interest in ICU Medical Inc.?
Short interest in the ICU Medical Inc. stock has plunged, decreasing by 50490.0 shares to total 0.31 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.26 million, data from Yahoo Finance shows. The increase of 16.11% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 2.23% of the overall float for the stock.
ICU Medical Inc.’s Biggest Shareholders: Who Owns ICU Medical Inc. [ICUI]?
Filings by Janus Capital Management LLC showed that the firm now holds a total of 2,947,263 shares or roughly 14.05% of the outstanding ICUI shares. This means their shares have increased by 308,854 from the 2,947,263 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, T. Rowe Price Associates, Inc. updated stake is worth $501,186,634. Details in the latest 13F filings reveal that The Vanguard Group, Inc. disposed off their -3.81% stake valued at $328,398,573 while BlackRock Fund Advisors cut theirs at $288,461,350. During the last quarter, The Vanguard Group, Inc. liquidated -68,975 of its shares in ICU Medical Inc. while BlackRock Fund Advisors sold -43,515 shares. The Nuance Investments LLC’s holdings currently number 729,677 shares at $160521643.23. According to the firm’s last 13F report, JPMorgan Investment Management, I shares in the company at filing stood at 617,811 shares, roughly $116,580,936.
ICUI Earnings Forecast For The Current Quarter
ICU Medical Inc. [ICUI] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $295.33M and an earnings per share of $1.51 for Dec 2020. Looking further ahead, the company is expected to report revenue of $300.25M at an EPS of $1.56 for Mar 2021. The estimates represent downside of 2.00% and 6.80% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
ICUI Earnings Estimates For The Current Year
For the financial year, ICU Medical Inc. [NASDAQ:ICUI] is expected to bring in revenue of $1.2B. The returns are nearly $10.0 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 6.88, lower than that of FY19 by -$1.28. Estimates put this year’s earnings growth at -15.70%, 6.80% for the next, and at an annual 16.00% over the next 5-year period. As for sales, forecasts are for an increase of 1.10% in the current fiscal year and a further 2.00% over the following year.